# Clinica Universidad de Navarra

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/clinica-universidad-de-navarra/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 69.4 |
| Citations | 1,135,580 |
| City | Pamplona |
| Country | ES |
| Description | Clinica Universidad de Navarra is a research organisation in Pamplona, ES. OpenAlex records 27,157 works and 1,135,580 citations for it. 6,602 researchers list it as their most recent affiliation. |
| Homepage | http://www.cun.es |
| OpenAlex ID | https://openalex.org/I4210135003 |
| Researchers | 6,602 |
| ROR ID | https://ror.org/03phm3r45 |
| Type | healthcare |
| Works | 27,157 |

## University papers

Showing 12 of 16.

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [A microRNA DNA methylation signature for human cancer metastasis](https://scholariq.org/papers/a-microrna-dna-methylation-signature-for-human-cancer-metastasis/)
- [Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer](https://scholariq.org/papers/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of/)
- [Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges](https://scholariq.org/papers/biomarkers-in-lung-cancer-screening-achievements-promises-and-challenges/)
- [Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest](https://scholariq.org/papers/assessing-the-relationship-between-lung-cancer-risk-and-emphysema-detected-on/)
- [Endovascular Repair of Acute Uncomplicated Aortic Type B Dissection Promotes Aortic Remodelling: 1 Year Results of the ADSORB Trial](https://scholariq.org/papers/endovascular-repair-of-acute-uncomplicated-aortic-type-b-dissection-promotes/)
- [A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer](https://scholariq.org/papers/a-prognostic-dna-methylation-signature-for-stage-i-non-small-cell-lung-cancer/)
- [Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression](https://scholariq.org/papers/anaphylatoxin-c5a-creates-a-favorable-microenvironment-for-lung-cancer/)
- [Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines](https://scholariq.org/papers/frequent-brg1-smarca4-inactivating-mutations-in-human-lung-cancer-cell-lines/)
- [Alternative splicing: an emerging topic in molecular and clinical oncology](https://scholariq.org/papers/alternative-splicing-an-emerging-topic-in-molecular-and-clinical-oncology/)
- [A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis](https://scholariq.org/papers/a-combined-pd-1-c5a-blockade-synergistically-protects-against-lung-cancer-growth/)

## University researchers

- [Luis M. Montuenga](https://scholariq.org/researchers/luis-m-montuenga/)

## University top topics

Showing 8 of 18.

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Historical Art and Architecture Studies](https://scholariq.org/topics/historical-art-and-architecture-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.